Abstract:Breast cancer is one of the most common types of cancer in females. While drug combinations have shown potential in breast cancer treatments, identifying new effective drug pairs is challenging due to the vast number of possible combinations among available compounds. Efforts have been made to accelerate the process with in silico predictions. Here, we developed a Boolean model of signaling pathways in breast cancer. The model was tailored to represent five breast cancer cell lines by integrating information about cell-line specific mutations, gene expression, and drug treatments. The models reproduced cell-line specific protein activities and drug-response behaviors in agreement with experimental data. Next, we proposed a calculation of protein synergy scores ( PSS s), determining the effect of drug combinations on individual proteins’ activities. The PSS s of selected proteins were used to investigate the synergistic effects of 150 drug combinations across five cancer cell lines. The comparison of the highest single agent (HSA) synergy scores between experiments and model predictions from the MDA-MB-231 cell line achieved the highest Pearson’s correlation coefficient of 0.58 with a great balance among the classification metrics (AUC = 0.74, sensitivity = 0.63, and specificity = 0.64). Finally, we clustered drug pairs into groups based on the selected PSS s to gain further insights into the mechanisms underlying the observed synergistic effects of drug pairs. Clustering analysis allowed us to identify distinct patterns in the protein activities that correspond to five different modes of synergy: 1) synergistic activation of FADD and BID (extrinsic apoptosis pathway), 2) synergistic inhibition of BCL2 (intrinsic apoptosis pathway), 3) synergistic inhibition of MTORC1, 4) synergistic inhibition of ESR1, and 5) synergistic inhibition of CYCLIN D. Our approach offers a mechanistic understanding of the efficacy of drug combinations and provides direction for selecting potential drug pairs worthy of further laboratory investigation.

Bimodal gene expression in cancer patients provides interpretable biomarkers for drug sensitivity

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Efficient parameterization of large-scale mechanistic models enables drug response prediction for cancer cell lines

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Explainable Machine Learning Models Using Robust Cancer Biomarkers Identification from Paired Differential Gene Expression

Learning and actioning general principles of cancer cell drug sensitivity

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data

Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers

Systematic identification of genomic markers of drug sensitivity in cancer cells

Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning

Precision Therapeutic Biomarker Identification with Application to the Cancer Genome Project

Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction

Characterization of Expression-Based Gene Clusters Gives Insights into Variation in Patient Response to Cancer Therapies

Evaluation of gene-drug common module identification methods using pharmacogenomics data